Annovis Bio, Inc.(ANVS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ANVS Annovis Bio, Inc.

Trading 07-27 15:55:27 EDT

1.67

+0.01

+0.60%

High1.72	Low1.64	Vol473.55K
Open1.69	D1 Closing1.66	Amplitude4.52%
Mkt Cap71.04M	Tradable Cap62.89M	Total Shares42.54M
T/O797.93K	T/O Rate1.26%	Tradable Shares37.66M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ANVS","market":"US","secType":"STK","nameCN":"Annovis Bio, Inc.","latestPrice":1.67,"timestamp":1785182119478,"preClose":1.66,"halted":0,"volume":473545,"delay":0,"changeRate":0.006024096385542174,"floatShares":37656941,"shares":42541900,"eps":-1.767283,"marketStatus":"Trading","change":0.01,"latestTime":"07-27 15:55:27 EDT","open":1.69,"high":1.715,"low":1.64,"amount":797931.84881,"amplitude":0.045181,"askPrice":1.68,"askSize":200,"bidPrice":1.67,"bidSize":218,"shortable":3,"etf":0,"ttmEps":-1.767283,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1785182400000},"marketStatusCode":2,"adr":0,"listingDate":1580274000000,"exchange":"NYSE","adjPreClose":1.66,"preHourTrading":{"tag":"盘前","latestPrice":1.69,"preClose":1.66,"latestTime":"08:48 EDT","volume":2838,"amount":4837.0511574,"timestamp":1785156521556,"change":0.03,"changeRate":0.018072,"amplitude":0.065964},"postHourTrading":{"tag":"盘后","latestPrice":1.68,"preClose":1.66,"latestTime":"19:57 EDT","volume":5870,"amount":9861.7277,"timestamp":1784937433960,"change":0.02,"changeRate":0.012048,"amplitude":0.012048},"volumeRatio":0.806284,"impliedVol":0.0032,"impliedVolPercentile":0.0319},"requestUrl":"/m/hq/s/ANVS","defaultTab":"news","newsList":[{"id":"2650018460","title":"Annovis Bio Completes Enrollment in Pivotal Alzheimer’s Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2650018460","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650018460?lang=en_us&edition=fundamental","pubTime":"2026-07-10 18:31","pubTimestamp":1783679463,"startTime":"0","endTime":"0","summary":"Annovis Bio ( ($ANVS) ) has provided an announcement. On July 7, 2026, Annovis Bio announced it had reached full enrollment in its pivotal Phase 3 ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/annovis-bio-completes-enrollment-in-pivotal-alzheimers-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/annovis-bio-completes-enrollment-in-pivotal-alzheimers-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ANVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650181831","title":"Annovis Bio Completes Enrollment in Phase 3 Early Alzheimer’s Trial of Buntanetap","url":"https://stock-news.laohu8.com/highlight/detail?id=2650181831","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650181831?lang=en_us&edition=fundamental","pubTime":"2026-07-10 18:04","pubTimestamp":1783677887,"startTime":"0","endTime":"0","summary":"Annovis Bio completes enrollment in Phase 3 early Alzheimer’s trial of buntanetapAnnovis Bio reached full enrollment in its pivotal Phase 3 trial of buntanetap for early Alzheimer’s disease.Trial enro","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260710:nNDL1Pwg9w:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ANVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650913794","title":"Analysts’ Top Healthcare Picks: Evolus (EOLS), Annovis Bio (ANVS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2650913794","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650913794?lang=en_us&edition=fundamental","pubTime":"2026-07-09 03:20","pubTimestamp":1783538403,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Evolus (EOLS) and Annovis Bio (ANVS) with bullish se...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-evolus-eols-annovis-bio-anvs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-evolus-eols-annovis-bio-anvs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","EOLS","LABU","XBI","XLV","BK4581","ANVS","LU0029874061.USD","HCSG","BK4588","BK4139","BK4585","BK4137","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649096494","title":"Annovis Bio Initiated at Buy by Roth Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2649096494","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649096494?lang=en_us&edition=fundamental","pubTime":"2026-07-08 17:18","pubTimestamp":1783502280,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ANVS/analyst-ratings(END) Dow Jones NewswiresJuly 08, 2026 05:18 ET","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANVS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649393039","title":"Annovis Bio initiated with a Buy at Roth Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2649393039","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649393039?lang=en_us&edition=fundamental","pubTime":"2026-07-08 04:16","pubTimestamp":1783455373,"startTime":"0","endTime":"0","summary":"Roth Capital initiated coverage of Annovis Bio (ANVS) with a Buy rating and $8 price target The firm is bullish on the company’s Alzheimer’s diseas...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/annovis-bio-initiated-with-a-buy-at-roth-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/annovis-bio-initiated-with-a-buy-at-roth-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ANVS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649984461","title":"Annovis Bio announces full enrollment for buntanetap trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2649984461","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649984461?lang=en_us&edition=fundamental","pubTime":"2026-07-07 19:20","pubTimestamp":1783423230,"startTime":"0","endTime":"0","summary":"Annovis Bio (ANVS) announced full enrollment of its pivotal Phase 3 trial evaluating buntanetap in patients with early AD. The trial enrolled 850 p...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/annovis-bio-announces-full-enrollment-for-buntanetap-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/annovis-bio-announces-full-enrollment-for-buntanetap-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BBC","PSIL","ANVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649848839","title":"Annovis Bio Reaches Full Enrollment in Phase 3 Early Alzheimer’s Trial of Buntanetap","url":"https://stock-news.laohu8.com/highlight/detail?id=2649848839","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649848839?lang=en_us&edition=fundamental","pubTime":"2026-07-07 19:02","pubTimestamp":1783422173,"startTime":"0","endTime":"0","summary":"Annovis Bio reaches full enrollment in Phase 3 early Alzheimer’s trial of buntanetapAnnovis Bio reached full enrollment of 850 patients in its pivotal Phase 3 trial of buntanetap for early Alzheimer’s","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nNDL148HpX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2T93.GBP","SG9999014013.SGD","BCDF","SG9999014021.USD","BK4139","IE00BN0W2W23.USD","BK4585","IE00BN0W2V16.EUR","IE00B3QW5Z07.USD","BK4588","IE00B64PRP62.GBP","ANVS","SG9999014005.SGD","IE00BGHQF748.EUR","NDAQ","BK4112","LU0314104364.USD","LU2095319765.USD","LU2210150020.SGD","LU2210149790.SGD","IE00BKPKM429.USD","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649981755","title":"Annovis Bio - Symptomatic Data Readout Expected Q1 2027, Disease-modifying Data Readout Expected Q1 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2649981755","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649981755?lang=en_us&edition=fundamental","pubTime":"2026-07-07 19:00","pubTimestamp":1783422002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nTUA1XQFTX:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ANVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649981714","title":"Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2649981714","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649981714?lang=en_us&edition=fundamental","pubTime":"2026-07-07 19:00","pubTimestamp":1783422002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nTUA1XQFTX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ANVS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649398175","title":"Annovis Bio - Preparing for Two Nda Submissions Following Data Readouts","url":"https://stock-news.laohu8.com/highlight/detail?id=2649398175","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649398175?lang=en_us&edition=fundamental","pubTime":"2026-07-07 19:00","pubTimestamp":1783422002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nTUA1XQFTX:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ANVS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648100205","title":"Press Release: Annovis Appoints Cheng Fang, Ph.d., as Chief Scientific Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2648100205","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648100205?lang=en_us&edition=fundamental","pubTime":"2026-07-01 20:01","pubTimestamp":1782907260,"startTime":"0","endTime":"0","summary":"MALVERN, Pa., July 01, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (\"Annovis\" or the \"Company\"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy,","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4132","LU1169589451.USD","PD","LU1169590202.USD","ANVS","BK4139","BK4023","AD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644727510","title":"Annovis Bio Shareholders Approve Governance and Compensation Changes","url":"https://stock-news.laohu8.com/highlight/detail?id=2644727510","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644727510?lang=en_us&edition=fundamental","pubTime":"2026-06-18 06:35","pubTimestamp":1781735737,"startTime":"0","endTime":"0","summary":"Annovis Bio ( ($ANVS) ) has issued an announcement. On June 17, 2026, Annovis Bio, Inc. held its 2026 Annual Meeting of Stockholders virtually, wit...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/annovis-bio-shareholders-approve-governance-and-compensation-changes?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/annovis-bio-shareholders-approve-governance-and-compensation-changes?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ANVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644724896","title":"Annovis Bio shareholders approve 2019 equity plan share increase to 5.5 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2644724896","media":"Reuters","labels":["shareholding","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644724896?lang=en_us&edition=fundamental","pubTime":"2026-06-18 04:51","pubTimestamp":1781729482,"startTime":"0","endTime":"0","summary":"Annovis Bio held its annual shareholder meeting on June 17, 2026.Shareholders backed a slate of director nominees for one-year terms.Ernst & Young was ratified as independent auditor.Investors adopted an amendment to the 2019 Equity Incentive Plan, lifting the share reserve to 5.5 million from 4 million.Shareholders endorsed a two-year cadence for future advisory votes on executive pay; the board expects to follow that schedule.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Annovis Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 17, 2026, and is solely responsible for the i","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nNDL8hDHB6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANVS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639611591","title":"Annovis Bio: Buy Rating Reiterated as Late-Stage Neurodegenerative Pipeline Advances; $8 Price Target Unchanged","url":"https://stock-news.laohu8.com/highlight/detail?id=2639611591","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639611591?lang=en_us&edition=fundamental","pubTime":"2026-05-29 05:15","pubTimestamp":1780002924,"startTime":"0","endTime":"0","summary":"Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Annovis Bio, retaining the price target of $8.00. Jason McCarthy has given his Buy...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/annovis-bio-buy-rating-reiterated-as-late-stage-neurodegenerative-pipeline-advances-8-price-target-unchanged-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/annovis-bio-buy-rating-reiterated-as-late-stage-neurodegenerative-pipeline-advances-8-price-target-unchanged-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SSI","ANVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638511754","title":"Annovis Bio Regains Nyse Listing Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2638511754","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638511754?lang=en_us&edition=fundamental","pubTime":"2026-05-26 20:00","pubTimestamp":1779796805,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nTUA5BJRBG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ANVS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638514586","title":"Annovis Bio Regains NYSE Listing Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2638514586","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638514586?lang=en_us&edition=fundamental","pubTime":"2026-05-26 20:00","pubTimestamp":1779796800,"startTime":"0","endTime":"0","summary":"MALVERN, Pa., May  26, 2026  (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/26/3301048/0/en/Annovis-Bio-Regains-NYSE-Listing-Compliance.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANVS","AD","BK4023","BK4132","PD","BK4139","LU1169590202.USD","NYSE","LU1169589451.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637363441","title":"Annovis Bio director Michael B Hoffman buys $141,027 of common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2637363441","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637363441?lang=en_us&edition=fundamental","pubTime":"2026-05-22 08:12","pubTimestamp":1779408722,"startTime":"0","endTime":"0","summary":"Annovis Bio director Michael B. Hoffman reported open-market purchases of 76,344 common shares at prices ranging from USD 1.75 to USD 1.9.An additional 223,357 shares were reported as held indirectly through the 2024 Hoffman Family Trust.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Annovis Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 21, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260522:nNDL39jCFH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Annovis Bio director Michael B Hoffman buys $141,027 of common shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ANVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637541879","title":"Annovis Bio Announces Dilutive Equity Offering for Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2637541879","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637541879?lang=en_us&edition=fundamental","pubTime":"2026-05-21 06:05","pubTimestamp":1779314732,"startTime":"0","endTime":"0","summary":"Annovis Bio ( ($ANVS) ) has issued an announcement. On May 20, 2026, Annovis Bio entered an underwriting agreement with Canaccord Genuity for a pub...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/annovis-bio-announces-dilutive-equity-offering-for-trials?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/annovis-bio-announces-dilutive-equity-offering-for-trials?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4585","BK4215","ANVS","EQR","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636842010","title":"BRIEF-Annovis Announces Pricing Of $15.0 Million Public Offering Of Common Stock And Accompanying Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2636842010","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636842010?lang=en_us&edition=fundamental","pubTime":"2026-05-20 20:43","pubTimestamp":1779281029,"startTime":"0","endTime":"0","summary":"BRIEF-Annovis Announces Pricing Of $15.0 Million Public Offering Of Common Stock And Accompanying WarrantsMay 20 (Reuters) - Annovis Bio Inc ANVS.N:ANNOVIS ANNOUNCES PRICING OF $15.0 MILLION PUBLIC OF","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260520:nTUAPJ225:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ANVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636684236","title":"Annovis Bio 7.9M share Spot Secondary priced at $1.90","url":"https://stock-news.laohu8.com/highlight/detail?id=2636684236","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636684236?lang=en_us&edition=fundamental","pubTime":"2026-05-20 20:20","pubTimestamp":1779279611,"startTime":"0","endTime":"0","summary":"The deal priced below last closing price of $1.94. Canaccord is acting as sole book running manager for the offering. Published first on TheFly – t...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/annovis-bio-7-9m-share-spot-secondary-priced-at-1-90-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/annovis-bio-7-9m-share-spot-secondary-priced-at-1-90-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ANVS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.annovisbio.com","stockEarnings":[{"period":"1week","weight":-0.046},{"period":"1month","weight":-0.0235},{"period":"3month","weight":-0.046},{"period":"6month","weight":-0.4485},{"period":"1year","weight":-0.4175},{"period":"ytd","weight":-0.5202}],"compareEarnings":[{"period":"1week","weight":-0.0059},{"period":"1month","weight":0.0078},{"period":"3month","weight":0.035},{"period":"6month","weight":0.0721},{"period":"1year","weight":0.1647},{"period":"ytd","weight":0.0836}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which is in Phase 3 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.040659},{"month":2,"riseRate":0.285714,"avgChangeRate":0.058949},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.056117},{"month":4,"riseRate":0.142857,"avgChangeRate":-0.132244},{"month":5,"riseRate":0.571429,"avgChangeRate":0.255652},{"month":6,"riseRate":0.428571,"avgChangeRate":0.139284},{"month":7,"riseRate":0.571429,"avgChangeRate":0.068803},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.070358},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.058484},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.073043},{"month":11,"riseRate":0.666667,"avgChangeRate":0.26823},{"month":12,"riseRate":0.333333,"avgChangeRate":0.124011}],"exchange":"NYSE","name":"Annovis Bio, Inc.","nameEN":"Annovis Bio, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Annovis Bio, Inc.(ANVS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Annovis Bio, Inc.(ANVS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Annovis Bio, Inc.,ANVS,Annovis Bio, Inc.股票,Annovis Bio, Inc.股票老虎,Annovis Bio, Inc.股票老虎国际,Annovis Bio, Inc.行情,Annovis Bio, Inc.股票行情,Annovis Bio, Inc.股价,Annovis Bio, Inc.股市,Annovis Bio, Inc.股票价格,Annovis Bio, Inc.股票交易,Annovis Bio, Inc.股票购买,Annovis Bio, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Annovis Bio, Inc.(ANVS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Annovis Bio, Inc.(ANVS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}